This clinical trial is focused on studying treatments for a type of lung cancer known as non-squamous non-small cell lung cancer (NSCLC). This specific form of lung cancer is characterized by high levels of a protein called PD-L1. The study will explore the effectiveness and safety of a new treatment combination involving two medications: Datopotamab deruxtecan (also known as Dato-DXd) and Rilvegostomig (also known as AZD2936). Additionally, the study will compare these treatments to another medication called Pembrolizumab, which is already used in treating this type of cancer.

The purpose of the study is to determine if the combination of Dato-DXd and Rilvegostomig, or Rilvegostomig alone, is more effective than Pembrolizumab in treating patients with advanced NSCLC. Participants in the study will receive one of these treatments, and some may receive a placebo. The study will monitor the progress of the disease and the overall health of the participants over time. The treatments will be administered through an intravenous infusion, which means they will be given directly into a vein.

Throughout the study, participants will have regular check-ups to assess their response to the treatment and to monitor any side effects. The study aims to provide valuable information on how these treatments can help manage NSCLC and improve the quality of life for those affected by this condition. The trial is expected to continue for several years, allowing researchers to gather comprehensive data on the long-term effects and benefits of the treatments being studied.